Acurx announces presentation and update of its pol iiic r&d pipeline at the world antimicrobial resistance scientific congress

Ibezapolstat is currently enrolling in a phase 2b trial for c. difficile infection in u.s. centers across the country and nearing its goal to reach a targeted 36 patients at which point an interim analysis of the unblinded primary clinical endpoint and safety data will be reviewed by an independent data monitoring committee ibezapolstat has received fda qidp and fast-track designation also presented was an update on the company's pre-clinical antibiotic program in lead optimization stage for systemic gram-positive bacterial infections, including acute bacterial skin and skin structure infections caused by mrsa the company's preclinical pipeline also targets systemic infections caused by other gram-positive bacteria such as vre and drsp which are expected to be qidp and fast-track eligible as product candidates advance in development staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking